摘要
目的 探讨醒脑静与纳洛酮治疗重型颅脑损伤后迁延性昏迷患者的疗效.方法 分析我院2011年1月～2013年1月收治的76例重型颅脑损伤后迁延性昏迷患者,随机分为对照组36例、治疗组40例.两组均给予常规治疗,对照组在此基础上加用纳洛酮,治疗组在此基础上加用醒脑静.比较两组临床疗效、生命体征、格拉斯哥昏迷量表（GCS）评分、远期生活质量评估量表（KPS）评分的变化.结果 对照组与治疗组临床总有效率分别为58.4％与82.5％,对照组呼吸系统与心血管系统异常发生率显著高于治疗组,对照组GCS评分与KPS评分均显著低于治疗组,两组比较差异均有统计学意义（P＜0.05）.结论 醒脑静与纳洛酮比较,在提高重型颅脑损伤后迁延性昏迷患者的临床治疗治愈率、减少呼吸及心脑血管事件的发生率及改善GCS评分与KPS评分均具有显著性意义,具有临床应用推广的价值.
Objective To explore the effect of naloxone and Xingnaojing in the treatment of patients with persisting coma after severe craniocerebral injury. Methods A total of 76 patients of persisting coma after severe craniocerebral trauma of our hospital from January 2011 to January 2013 were analyzed and divided into the control group（36 cases）, which used naloxone based on the conventional treatment, and the treatment group （40 cases）, which used Xingnaojing injection based on the conventional treatment. The clinical curative effect, vital signs, Glasgow Coma Scale （GCS） score, the changes of long term quality of life assessment scale （KPS） score of two groups were compared. Results The total clinical effective rates of two groups were 58.4% and 82.5%. The respiratory and cardiovascular system abnormal rates of the control group were significantly higher than that in the treatment group. The GCS score and KPS score of control group were significantly lower than the treatment group. The comparison between two groups was statistically significant （P 〈 0.05）. Conclusion Xingnaojing can improve the clinical treatment of patients with persisting coma after severe craniocerebral injury compared with naloxone, reduce the incidence of respiratory and cardiovascular and cerebrovascular diseases, improve the GCS score and KPS score significantly and it is worthy of clinical application.
出处
《中国现代医生》
2014年第11期45-47,共3页
China Modern Doctor
关键词
重型颅脑损伤
迁延性昏迷
醒脑静
纳洛酮
Severe craniocerebral injury
Persistent coma
Xingnaojing injection
Naloxone
